Symbols / APYX
APYX Chart
About
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 145.24M |
| Enterprise Value | 149.69M | Income | -14.54M | Sales | 47.90M |
| Book/sh | 0.15 | Cash/sh | 0.66 | Dividend Yield | — |
| Payout | 0.00% | Employees | 220 | IPO | — |
| P/E | — | Forward P/E | -9.52 | PEG | — |
| P/S | 3.03 | P/B | 22.84 | P/C | — |
| EV/EBITDA | -16.76 | EV/Sales | 3.12 | Quick Ratio | 3.47 |
| Current Ratio | 4.44 | Debt/Eq | 644.93 | LT Debt/Eq | — |
| EPS (ttm) | -0.36 | EPS next Y | -0.37 | EPS Growth | — |
| Revenue Growth | 12.10% | Earnings | 2026-03-12 | ROA | -10.06% |
| ROE | -168.13% | ROIC | — | Gross Margin | 62.65% |
| Oper. Margin | -6.46% | Profit Margin | -30.35% | Shs Outstand | 41.03M |
| Shs Float | 26.40M | Short Float | 0.33% | Short Ratio | 1.01 |
| Short Interest | — | 52W High | 4.50 | 52W Low | 0.76 |
| Beta | 1.58 | Avg Volume | 107.62K | Volume | 126.00 |
| Target Price | $6.00 | Recom | Buy | Prev Close | $3.54 |
| Price | $3.54 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$3.54
Latest analyst target
3. DCF / Fair value
$-2.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.54
Low
$5.00
High
$8.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-16 | init | Roth Capital | — → Buy | $6 |
| 2025-11-12 | up | Citizens | Market Perform → Market Outperform | $8 |
| 2024-10-17 | init | BTIG | — → Neutral | — |
| 2024-09-16 | reit | JMP Securities | — → Market Perform | — |
| 2023-11-10 | main | Stephens & Co. | Overweight → Overweight | $5 |
| 2023-08-11 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2023-07-14 | init | Stephens & Co. | — → Overweight | $8 |
| 2023-06-15 | main | Lake Street | — → Buy | $9 |
| 2023-05-24 | reit | JMP Securities | — → Market Perform | — |
| 2023-05-12 | main | Lake Street | Buy → Buy | $6 |
| 2022-08-12 | main | Piper Sandler | — → Overweight | $12 |
| 2022-07-19 | main | Lake Street | — → Buy | $17 |
| 2022-05-20 | init | Lake Street | — → Buy | $12 |
| 2021-08-13 | main | JMP Securities | — → Market Outperform | $14 |
| 2020-05-12 | main | JMP Securities | — → Market Outperform | $5 |
| 2019-11-12 | main | Piper Sandler | — → Overweight | $10 |
| 2019-04-02 | main | JMP Securities | Market Outperform → Market Outperform | $8 |
- Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock - Yahoo Finance ue, 18 Nov 2025 08
- Breakouts Watch: Whats the RSI of APYX stock - 2025 Trade Ideas & Smart Money Movement Tracker - baoquankhu1.vn ue, 24 Feb 2026 23
- Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)? - simplywall.st Fri, 07 Nov 2025 08
- Apyx Medical Stock Strengthens On AYON Launch And U.S. Aesthetics Demand - RTTNews ue, 13 Jan 2026 08
- Apyx Medical launches public offering of common stock - Investing.com Mon, 17 Nov 2025 08
- Roth Capital Initiates Coverage of Apyx Medical (APYX) with Buy Recommendation - Nasdaq ue, 16 Dec 2025 08
- Certain Options of Apyx Medical Corporation are subject to a Lock-Up Agreement Ending on 17-FEB-2026. - marketscreener.com ue, 17 Feb 2026 00
- Apyx Medical Corporation to Release Third Quarter Fiscal Year 2025 Financial Results on November 6th - Quiver Quantitative hu, 23 Oct 2025 07
- Apyx Medical prices public offering of common stock at $3.62 per share - Investing.com ue, 18 Nov 2025 08
- Apyx Medical Corporation to Release Second Quarter Fiscal Year 2025 Financial Results on August 7th - Nasdaq hu, 24 Jul 2025 07
- Apyx Medical Corporation Reports Third Quarter 2025 Financial Results - Yahoo Finance hu, 06 Nov 2025 08
- 510(k) Submission Seeks FDA Label Expansion to Add AYON Power Liposuction; Nationwide launch began Sept 2025 - Stock Titan Mon, 13 Oct 2025 07
- New Analyst Forecast: $APYX Given $6 Price Target - Quiver Quantitative ue, 16 Dec 2025 08
- How The AYON Story Is Reshaping The Apyx Medical (APYX) Investment Case - Yahoo Finance Wed, 07 Jan 2026 08
- Apyx Medical - Getting In Shape With Renuvion And AYON - RTTNews ue, 24 Jun 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 12000 | 21600 | — | Conversion of Exercise of derivative security at price 1.80 per share. | ROMAN SHAWN DAVID | Chief Operating Officer | — | 2026-01-27 00:00:00 | I |
| 1 | 5336 | 6030 | — | Purchase at price 1.13 per share. | HILL MATTHEW C | Chief Financial Officer | — | 2024-08-13 00:00:00 | D |
| 2 | 6000 | 6780 | — | Purchase at price 1.13 per share. | HILL MATTHEW C | Chief Financial Officer | — | 2024-08-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -45.14K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.11 | 0.21 | 0.27 |
| NormalizedEBITDA | -16.80M | -17.72M | -22.01M | -13.91M |
| TotalUnusualItems | 0.00 | -396.00K | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -396.00K | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -23.46M | -18.71M | -23.18M | -15.17M |
| ReconciledDepreciation | 599.00K | 692.00K | 890.00K | 903.00K |
| ReconciledCostOfRevenue | 18.74M | 18.59M | 15.38M | 14.92M |
| EBITDA | -16.80M | -18.11M | -22.01M | -13.91M |
| EBIT | -17.40M | -18.80M | -22.90M | -14.81M |
| NetInterestIncome | -4.30M | -1.56M | 142.00K | 1.00K |
| InterestExpense | 5.91M | 2.48M | 15.00K | 10.00K |
| InterestIncome | 1.61M | 921.00K | 157.00K | 11.00K |
| NormalizedIncome | -23.46M | -18.36M | -23.18M | -15.17M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -23.46M | -18.71M | -23.18M | -15.17M |
| TotalExpenses | 66.95M | 72.30M | 68.07M | 62.97M |
| TotalOperatingIncomeAsReported | -18.84M | -17.26M | -23.56M | -14.45M |
| DilutedAverageShares | 35.54M | 34.62M | 34.52M | 34.33M |
| BasicAverageShares | 35.54M | 34.62M | 34.52M | 34.33M |
| DilutedEPS | -0.66 | -0.54 | -0.67 | -0.44 |
| BasicEPS | -0.66 | -0.54 | -0.67 | -0.44 |
| DilutedNIAvailtoComStockholders | -23.46M | -18.71M | -23.18M | -15.17M |
| NetIncomeCommonStockholders | -23.46M | -18.71M | -23.18M | -15.17M |
| NetIncome | -23.46M | -18.71M | -23.18M | -15.17M |
| MinorityInterests | 96.00K | 137.00K | 94.00K | 28.00K |
| NetIncomeIncludingNoncontrollingInterests | -23.56M | -18.85M | -23.28M | -15.20M |
| NetIncomeContinuousOperations | -23.56M | -18.85M | -23.28M | -15.20M |
| TaxProvision | 252.00K | -2.43M | 367.00K | 380.00K |
| PretaxIncome | -23.31M | -21.28M | -22.91M | -14.82M |
| OtherIncomeExpense | -161.00K | 226.00K | 509.00K | -373.00K |
| OtherNonOperatingIncomeExpenses | -161.00K | 622.00K | 509.00K | -373.00K |
| SpecialIncomeCharges | 0.00 | -396.00K | 0.00 | |
| OtherSpecialCharges | 396.00K | |||
| NetNonOperatingInterestIncomeExpense | -4.30M | -1.56M | 142.00K | 1.00K |
| InterestExpenseNonOperating | 5.91M | 2.48M | 15.00K | 10.00K |
| InterestIncomeNonOperating | 1.61M | 921.00K | 157.00K | 11.00K |
| OperatingIncome | -18.84M | -19.95M | -23.56M | -14.45M |
| OperatingExpense | 48.20M | 53.71M | 52.69M | 48.05M |
| ResearchAndDevelopment | 5.08M | 5.44M | 4.54M | 4.32M |
| SellingGeneralAndAdministration | 43.12M | 48.27M | 48.15M | 43.73M |
| GeneralAndAdministrativeExpense | 43.12M | 48.27M | 48.15M | 43.73M |
| OtherGandA | 25.77M | 29.23M | 29.53M | 26.21M |
| SalariesAndWages | 17.35M | 19.04M | 18.62M | 17.52M |
| GrossProfit | 29.36M | 33.76M | 29.13M | 33.60M |
| CostOfRevenue | 18.74M | 18.59M | 15.38M | 14.92M |
| TotalRevenue | 48.10M | 52.35M | 44.51M | 48.52M |
| OperatingRevenue | 48.10M | 52.35M | 44.51M | 48.52M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 37.79M | 34.64M | 34.60M | 34.41M |
| ShareIssued | 37.79M | 34.64M | 34.60M | 34.41M |
| NetDebt | 2.15M | |||
| TotalDebt | 38.76M | 38.50M | 796.00K | 305.00K |
| TangibleBookValue | 14.21M | 26.70M | 37.58M | 53.70M |
| InvestedCapital | 48.10M | 59.89M | 37.58M | 53.70M |
| WorkingCapital | 45.72M | 57.62M | 31.12M | 47.53M |
| NetTangibleAssets | 14.21M | 26.70M | 37.58M | 53.70M |
| CapitalLeaseObligations | 4.87M | 5.32M | 796.00K | 305.00K |
| CommonStockEquity | 14.21M | 26.70M | 37.58M | 53.70M |
| TotalCapitalization | 48.10M | 59.89M | 37.58M | 53.70M |
| TotalEquityGrossMinorityInterest | 14.34M | 26.92M | 37.79M | 54.01M |
| MinorityInterest | 125.00K | 221.00K | 211.00K | 305.00K |
| StockholdersEquity | 14.21M | 26.70M | 37.58M | 53.70M |
| RetainedEarnings | -77.91M | -54.45M | -35.73M | -12.55M |
| AdditionalPaidInCapital | 92.08M | 81.11M | 73.28M | 66.22M |
| CapitalStock | 38.00K | 35.00K | 35.00K | 34.00K |
| CommonStock | 38.00K | 35.00K | 35.00K | 34.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 50.51M | 52.32M | 13.98M | 14.71M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 39.79M | 39.58M | 2.13M | 1.51M |
| OtherNonCurrentLiabilities | 259.00K | 198.00K | 181.00K | 166.00K |
| NonCurrentDeferredLiabilities | 1.12M | 1.25M | 1.41M | 1.32M |
| NonCurrentDeferredRevenue | 1.12M | 1.25M | 1.41M | 1.32M |
| LongTermDebtAndCapitalLeaseObligation | 38.41M | 38.13M | 543.00K | 18.00K |
| LongTermCapitalLeaseObligation | 4.52M | 4.95M | 543.00K | 18.00K |
| LongTermDebt | 33.89M | 33.19M | ||
| CurrentLiabilities | 10.72M | 12.74M | 11.85M | 13.21M |
| OtherCurrentLiabilities | 2.08M | 1.86M | ||
| CurrentDeferredLiabilities | 693.00K | 488.00K | 853.00K | 533.00K |
| CurrentDeferredRevenue | 693.00K | 488.00K | 853.00K | 533.00K |
| CurrentDebtAndCapitalLeaseObligation | 355.00K | 367.00K | 253.00K | 287.00K |
| CurrentCapitalLeaseObligation | 355.00K | 367.00K | 253.00K | 287.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 1.54M | 0.00 | 2.12M |
| PayablesAndAccruedExpenses | 9.67M | 10.34M | 10.74M | 10.27M |
| CurrentAccruedExpenses | 7.06M | 7.63M | 6.00M | 5.35M |
| Payables | 2.62M | 2.71M | 4.75M | 4.92M |
| TotalTaxPayable | 0.00 | 2.08M | 2.29M | |
| AccountsPayable | 2.62M | 2.71M | 2.67M | 2.63M |
| TotalAssets | 64.84M | 79.24M | 51.77M | 68.72M |
| TotalNonCurrentAssets | 8.40M | 8.88M | 8.80M | 7.98M |
| OtherNonCurrentAssets | 1.66M | 1.73M | 1.22M | 1.11M |
| NetPPE | 6.74M | 7.15M | 7.59M | 6.87M |
| AccumulatedDepreciation | -3.99M | -3.52M | -5.04M | -5.32M |
| GrossPPE | 10.73M | 10.67M | 12.63M | 12.19M |
| Leases | 281.00K | 212.00K | 178.00K | 171.00K |
| ConstructionInProgress | 635.00K | 400.00K | 507.00K | 654.00K |
| OtherProperties | 5.71M | 6.15M | 1.67M | 1.16M |
| MachineryFurnitureEquipment | 4.10M | 3.90M | 4.24M | 4.18M |
| BuildingsAndImprovements | 0.00 | 4.43M | 4.43M | |
| LandAndImprovements | 0.00 | 1.60M | 1.60M | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 56.44M | 70.36M | 42.97M | 60.74M |
| OtherCurrentAssets | 1.66M | 2.76M | 2.74M | 1.93M |
| PrepaidAssets | 1.93M | |||
| Inventory | 7.56M | 9.92M | 11.80M | 6.78M |
| InventoriesAdjustmentsAllowances | -1.03M | -875.00K | -457.00K | -263.00K |
| FinishedGoods | 2.71M | 4.43M | 5.12M | 2.00M |
| WorkInProcess | 1.92M | 2.26M | 2.16M | 1.44M |
| RawMaterials | 3.97M | 4.11M | 4.98M | 3.60M |
| Receivables | 15.48M | 14.02M | 18.25M | 21.16M |
| OtherReceivables | 30.00K | 99.00K | 483.00K | |
| TaxesReceivable | 0.00 | 7.54M | 7.64M | |
| AccountsReceivable | 15.48M | 14.02M | 10.60M | 13.04M |
| AllowanceForDoubtfulAccountsReceivable | -1.00M | -608.00K | -668.00K | -430.00K |
| GrossAccountsReceivable | 16.48M | 14.63M | 11.27M | 13.47M |
| CashCashEquivalentsAndShortTermInvestments | 31.74M | 43.65M | 10.19M | 30.87M |
| CashAndCashEquivalents | 31.74M | 43.65M | 10.19M | 30.87M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.77M | -5.78M | -21.29M | -11.17M |
| RepaymentOfDebt | -20.00K | -11.07M | -148.00K | -238.00K |
| IssuanceOfDebt | 0.00 | 46.11M | 0.00 | |
| IssuanceOfCapitalStock | 7.00M | 0.00 | ||
| CapitalExpenditure | -722.00K | -533.00K | -1.01M | -723.00K |
| InterestPaidSupplementalData | 4.75M | 1.94M | 15.00K | 10.00K |
| IncomeTaxPaidSupplementalData | 382.00K | 329.00K | 128.00K | 111.00K |
| EndCashPosition | 31.74M | 43.65M | 10.19M | 30.87M |
| BeginningCashPosition | 43.65M | 10.19M | 30.87M | 41.91M |
| EffectOfExchangeRateChanges | 113.00K | -191.00K | 395.00K | 103.00K |
| ChangesInCash | -12.02M | 33.65M | -21.07M | -11.15M |
| FinancingCashFlow | 6.75M | 32.17M | 217.00K | 24.00K |
| CashFlowFromContinuingFinancingActivities | 6.75M | 32.17M | 217.00K | 24.00K |
| NetOtherFinancingCharges | -235.00K | -2.96M | 195.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 86.00K | 365.00K | 67.00K |
| NetCommonStockIssuance | 7.00M | 0.00 | ||
| CommonStockIssuance | 7.00M | 0.00 | ||
| NetIssuancePaymentsOfDebt | -20.00K | 35.04M | -148.00K | -238.00K |
| NetLongTermDebtIssuance | -20.00K | 35.04M | -148.00K | -238.00K |
| LongTermDebtPayments | -20.00K | -11.07M | -148.00K | -238.00K |
| LongTermDebtIssuance | 0.00 | 46.11M | 0.00 | |
| InvestingCashFlow | -722.00K | 6.73M | -1.01M | -723.00K |
| CashFlowFromContinuingInvestingActivities | -722.00K | 6.73M | -1.01M | -723.00K |
| NetPPEPurchaseAndSale | -722.00K | 6.73M | -1.01M | -723.00K |
| SaleOfPPE | 0.00 | 7.27M | 0.00 | |
| PurchaseOfPPE | -722.00K | -533.00K | -1.01M | -723.00K |
| OperatingCashFlow | -18.05M | -5.25M | -20.28M | -10.45M |
| CashFlowFromContinuingOperatingActivities | -18.05M | -5.25M | -20.28M | -10.45M |
| ChangeInWorkingCapital | -1.25M | 5.54M | -5.22M | -1.84M |
| ChangeInPayablesAndAccruedExpense | -2.33M | 301.00K | -1.14M | 4.55M |
| ChangeInAccruedExpense | -2.27M | 276.00K | -1.21M | 3.40M |
| ChangeInPayable | -63.00K | 25.00K | 67.00K | 1.15M |
| ChangeInAccountPayable | -63.00K | 25.00K | 67.00K | 1.15M |
| ChangeInPrepaidAssets | 857.00K | -188.00K | -523.00K | 1.35M |
| ChangeInInventory | 2.26M | 1.46M | -5.57M | -2.86M |
| ChangeInReceivables | -2.04M | 3.97M | 2.02M | -4.89M |
| ChangesInAccountReceivables | -2.04M | -3.57M | 1.92M | -4.90M |
| OtherNonCashItems | 1.27M | 632.00K | ||
| StockBasedCompensation | 4.01M | 5.11M | 6.70M | 5.09M |
| ProvisionandWriteOffofAssets | 863.00K | 1.06M | 553.00K | 555.00K |
| DepreciationAmortizationDepletion | 599.00K | 692.00K | 890.00K | 903.00K |
| DepreciationAndAmortization | 599.00K | 692.00K | 890.00K | 903.00K |
| OperatingGainsLosses | 13.00K | 557.00K | 75.00K | 48.00K |
| GainLossOnSaleOfPPE | 13.00K | -2.53M | 75.00K | 48.00K |
| NetIncomeFromContinuingOperations | -23.56M | -18.85M | -23.28M | -15.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for APYX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|